Takeda's psoriasis pill succeeds in late-stage studies

 

• About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies
• A significantly greater PASI 75 response rate versus placebo was observed as early as week 4
• Safety profile consistent with Phase 2b studies with no new safety signals identified

https://www.takeda.com/newsroom/newsreleases/2026/zasocitinib-phase3-clinical-trial-results/